The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: Implications for diagnosis, classification, and management

Blood

Volumn 103, Issue 8, 2004, Pages 2879-2891

  Gotlib, Jason ^a   Cools, Jan ^c   Malone III, James M ^c   Schrier, Stanley L ^c   Gilliland, D Gary ^b   Coutré, Steven E ^c  

^a STANFORD CANCER INSTITUTE   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

CANCER REGRESSION; CARDIOGENIC SHOCK; CHROMOSOME 4; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; EOSINOPHILIC LEUKEMIA; FIP1L1 GENE; GENE; GENE DELETION; GENE FUSION; GENE MUTATION; GENE TARGETING; HEADACHE; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; MOLECULAR BIOLOGY; MYOCARDITIS; PALLIATIVE THERAPY; PATHOGENESIS; PDGFRA GENE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; ALGORITHM; CLASSIFICATION; CYTOGENETICS; GENETICS; IMMUNOLOGY; PROGNOSIS; T LYMPHOCYTE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CYTOGENETICS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; T-LYMPHOCYTES;

EID: 1842474941     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-1824     Document Type: Review

References (192)

1. Bain BJ. Hypereosinophilia. Curr Opin Hematol. 2000;7:21-25.
2. Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic hypereosinophilia. N Engl J Med. 1999;341:1112-1120.
3. Cools J, DeAngelo DJ, Gollib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
4. Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97:78-92.
5. Alfaham MA, Ferguson SD, Sihra B, Davies J. The idiopathic hypereosinophilic syndrome. Arch Dis Child 1987;62:601-613.
6. Wynn SR, Sachs MI, Keating MU, et al. Idiopathic hypereosinophilic syndrome in a 5 1/2-month-old infant. J Pediatr. 1987;111:94-97.
7. Bakhshi S, Hamre M, Mohamed AM, Feldman G, Ravindranath Y. t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol. 2003;25:82-84.
8. Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68:1220-1229.
9. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine. 1975;54:1-27.
10. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:29-31.
11. Forrest DL, Horsman DE, Jensen CL, et al. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1998;107:65-68.
12. Goldman JM, Najfeld V, Th'ng, KH. Agar culture and chromosome analysis of eosinophilic leukaemia. J Clin Pathol. 1975;28:956-961.
13. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999;93:1651-1657.
14. Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome. Blood. 1994;84:349-350.
15. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol. 2003;121:203-223.
16. Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol. 1996;95:2-9.
17. Brito-Babapulle F. Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev. 1997;11:129-145.
18. Roufosse F, Cogan R, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med. 2003;54:169-184.
19. Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52:1-22.
20. Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris). 1989;140:253-257.
21. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
22. Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood. 1981;58:1012-1020.
23. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987;1:643-647.
24. Venge P, Dahl R, Hallgren R, Olsson I. Cationic proteins of human eosinophils and their role in the inflammatory reaction. In: Mahmoud AAF, Austen KF, eds. The Eosinophil in Health and Disease. New York, NY: Grune and Stratton; 1980:131-144.
25. Tanino M, Kitamura K, Ohta G, Yamamoto Y, Sugioka G. Hypereosinophilic syndrome with extensive myocardial involvement and mitral valve thrombus instead of mural thrombi. Acta Pathol Jpn. 1983;33:1233-1242.
26. Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacement for hypereosinophilic syndrome. Cardiol Young. 2002;12:67-70.
27. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000;86:110-113.
28. DePace NL, Nestico PF, Morganroth J, et al. Dilated cardiomyopathy in the idiopathic hypereosinophilic syndrome. Am J Cardiol. 1983;52:1359-1360.
29. Baratta L, Afeltra A, Delfino M, De Castro S, Giorgino F, Rossi-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy - case report and review of the literature. Angiology. 2002;53:465-470.
30. Virmani R, Chun PK, Dunn BE, Hartmen D, McAllister HA. Eosinophilic constrictive pericarditis. Am Heart J. 1984;107:803-807.
31. Lui CY, Makoui C. Severe constrictive pericarditis as an unsuspected cause of death in a patient with idiopathic hypereosinophilic syndrome and restrictive cardiomyopathy. Clin Cardiol. 1988;11:502-504.
32. Corssmit EP, Trip MD, Durrer JD, Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology. 1999;91:272-276.
33. Hayashi S, Isobe M, Okubo Y, Suzuki J, Yazaki Y, Sekiguchi M. Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens. Heart Vessels. 1999;14:104-108.
34. Ejima J, Ohmura I, Kaji Y, Tsuda Y, Kanaya S, Fujino T. Diffuse endocardial thrombus in left ventricle associated with a case of hypereosinophilic syndrome. Jpn Heart J. 1991;32:267-272.
35. Harley JB, McIntosh XL, Kirklin JJ, et al. Atrioventricular valve replacement in the idiopathic hypereosinophilic syndrome. Am J Med. 1982;73:77-81.
36. Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1988;46:570-571.
37. Cameron J, Radford DJ, Howell J, O'Brien MF. Hypereosinophilic heart disease Med. J Aust. 1985;143:408-410.
38. Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol. 2001;45:524-527.
39. Rauch AE, Amyot KM, Dunn HG, Ng B, Wilner G. Hypereosinophilic syndrome and myocardial infarction in a 15-year-old. Pediatr Pathol Lab Med. 1997;17:469-486.
40. Kazmierowski JA, Chusid MJ, Parrillo JE, Fauci AS, Wolff SM. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol. 1978;114:531-535.
41. DeYampert NM, Beck LA. Eosinophilia and multiple erythematous indurated plaques. Idiopathic hypereosinophilic syndrome (IHS). Arch Dermatol. 1997;133:1581-1584.
42. Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritis associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol. 1990;122:103-106.
43. Lee ML, Fischer G, Gow E. Hypereosinophilic syndrome presenting with erythroderma. Australas J Dermatol. 1988;29:95-101.
44. Leiferman KM, O'Duffy JD, Perry HO, Greipp PR, Giulianì ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA. 1982;247:1018-1020.
45. Parker CJ. Hypereosinophilic syndrome with cutaneous blisters and bowel necrosis. Australas J Dermatol. 1988;29:103-106.
46. Fitzpatrick JE, Johnson C, Simon P, Owenby J. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. Am J Dermatopathol. 1987;9:419-422.
47. Narayan S, Ezughah F, Standen GR, Pawade J, Kennedy CTC. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol. 1993;148:817-820.
48. Sanchez JL, Padilla MA. Hypereosinophilic syndrome. Cutis. 1982;29:490-495.
49. Bogenrieder T, Griese DP, Schiffner R, et al. Well's syndrome associated with idiopathic hypereosinophilic syndrome. Br J Dermatol. 1997;137:978-982.
50. Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985;102:109-114.
51. Wichman A, Buchthal F, Pezeshkpour GH, Fauci AS. Peripheral neuropathy in hypereosinophilic syndrome. Neurology. 1985;35:1140-1145.
52. Kwon SU, Kim JC, Kim JS. Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy. J Neurol. 2001;248:279-284.
53. Kaplan PW, Waterbury L, Kawas C, Bolla-Wilson K, Durack D. Reversible dementia with idiopathic hypereosinophilic syndrome. Neurology. 1989;39:1388-1391.
54. Prick JJ, Gabreels-Festen AA, Korten JJ, van der Wiel TW. Neurological manifestations of the hypereosinophilic syndrome (HES). Clin Neurol Neurosurg. 1988;90:269-273.
55. Weaver DF, Hefferman LP, Purdy RA, Ing VW. Eosinophil-induced neurotoxicity: axonal neuropathy, cerebral infarction and dementia. Neurology. 1988;38:144-146.
56. Diaz F, Collazos J. Reversible cerebellar involvement in the idiopathic hypereosinophilic syndrome. Postgrad Med J. 1999;75:477-479.
57. Weingarten JS, O'Sheal SF, Margolis WS. Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature. Am J Med. 1985;78:674-676.
58. Slabbynck H, Impens N, Naegels S, Dewaele M, Schandevyl W. Idiopathic hypereosinophilic syndrome-related pulmonary involvement diagnosed by bronchoalveolar lavage. Chest. 1992;101:1178-1180.
59. Cordier JF, Faure M, Hermier C, Brune J. Pleural effusions in an overlap syndrome of idiopathic hypereosinophilic syndrome and erythema elevatum diutinum. Eur Respir J. 1990;3:115-118.
60. Epstein DM, Taortaina V, Gefter WB, Miller WT. The hypereosinophilic syndrome. Radiology. 1981;140:59-62.
61. Kang EY, Shim JJ, Kim JS, Kim KI. Pulmonary involvement of idiopathic hypereosinophilic syndrome: CT findings in five patients. J Comput Assist Tomogr. 1997;21:612-615.
62. Winn RE, Kollef MH, Meyer JI. Pulmonary involvement in the hypereosinophilic syndrome. Chest. 1994;105:656-660.
63. Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood. 1981;58:1021-1026.
64. Nam KJ, Jung WJ, Choi JC, et al. Hepatic involvement in hypereosinophilia: sonographic findings. J Ultrasound Med. 1999;18:475-479.
65. Foong A, Scholes JV, Gleich GJ, Kephart GM, Holt PR. Eosinophil-induced chronic active hepatitis in the idiopathic hypereosinophilic syndrome. Hepatology 1991;13:1090-1094.
66. Ung KA, Remotti H, Olsson R, Eosinophilic hepatic necrosis in hypereosinophilic syndrome. J Clin Gastroenterol. 2000;31:323-327.
67. Elouaer-Blanc L, Zafrani ES, Farcet JP, Saint-Marc Girardin MF, Mathieu D, Dhumeaux D. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med 1985;145:751-753.
68. Grauer L, Padilla VM III, Bouza L, Barkin JS. Eosinophilic sclerosing cholangitis associated with hypereosinaphilic syndrome. Am J Gastroenterol. 1993;88:1764-1769.
69. Tajima K, Katagiri T. Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Dig Dis Sci. 1996;41:282-288.
70. Dillon JF, Finlayson ND. Idiopathic hypereosinophilic syndrome presenting as intrahepatic cholestatic jaundice. Am J Gastroenterol. 1994;89:1254-1255.
71. Binaghi M, Perrenoud F, Dhermy P, Coscas G. Hypereosinophilic syndrome with ocular involvement. J Fr Ophtalmol. 1985;8:309-314.
72. Chaine G, Davies J, Kohner EM, Hawarth S, Spry CJ. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology. 1982;89:1348-1356.
73. Farcet, JP, Binaghi M, Kuentz M, et al. A hypereosinophilic syndrome with retinal arteritis and tuberculosis. Arch Intern Med. 1982;142:625-627.
74. Bozkir N, Stern GA. Ocular manifestations of the idiopathic hypereasinophilic syndrome. Am J Ophthalmol. 1992;113:456-458.
75. Catalano L, Scala A, Rotoli B. Adie's syndrome (benign pupillotonia) and hypereosinophilic syndrome. Haematologica. 1988;73:549.
76. Vandewiele IA, Maeyaert BM, Van Cutsem EJ, Geboes KR, Knockaert DC. Massive eosinophilic ascites: differential diagnosis between idiopathic hypereosinophilic syndrome and eosinophilic gastroenteritis. Acta Clin Belg. 1991;46:37-41.
77. Bellaiche G, Fontaine H, Choudat L, Lusina D, Ley G, Slama JL. Pancreatic involvement, ascites and diarrhea in idiopathic hypereosinophilic syndrome. Gastroenterol Clin Biol. 1997;21:519-522.
78. Shah AM, Joglekar M. Eosinophilic colitis as a complication of the hypereosinophilic syndrome. Postgrad Med J. 1987;63:485-487.
79. Prattichizzo FA, Bemini L. An idiopathic hypereosinophilic syndrome mimicking seronegative rheumatoid arthritis: 20 year follow up with clinical and laboratory findings. Clin Exp Rheumatol. 1992;10:79-81.
80. Brogadir SP, Goldwein MI, Schurnacher HR. A hypereosinophilic syndrome mimicking rheumatoid arthritis. Am J Med. 1980;69:799-802.
81. Anders HJ, Schattenkirchner M. Destructive joint lesions and bursitis in idiopathic hypereosinophilic syndrome. Rheumatology (Oxford). 1999;38:185-186.
82. Atanes A, Fernandez V, Nunez R, et al. Idiopathic eosinophilic synovitis. Case report and review of the literature. Scand J Rheumatol. 1996;25:183-185.
83. Layzer RB, Shearn MA, Satya-Murti S. Eosinophilic polymyositis. Ann Neurol. 1977;1:65-71.
84. Takekawa M, Imai K, Adachi M, et al. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med. 1992;31:1262-1266.
85. Peison B, Benisch B, Lim M, Chin JC. Idiopathic hypereosinophilic syndrome with polymyositis. South Med J. 1988;81:403-406.
86. Pickering MC, Wallport MJ. Eosinophilic myopathic syndromes. Curr Opin Rheumatol. 1998;10:504-510.
87. Hirszel P, Cashell AW, Whelan TV, Dolan R, Yoshihashi A. Urinary Charcot-Leyden crystals in the hypereosinophilic syndrome with acute renal failure. Am J Kidney Dis. 1988;12:319-322.
88. Nakahara C, Kamoda T, Kinusaga H, et al. Simultaneous onset of nephrotic syndrome and insulin-dependent diabetes mellitus in a case with hypereosinophilic syndrome. Clin Nelphrol. 2000;53:312-314.
89. Choi YJ, Lee JD, Yang KH, et al. Immunotactoid glomerulopathy associated with hypereosinophilic syndrome. Am J Nelphrol. 1998;18:337-343.
90. Richardson P, Dickinson G, Nash S, Hoffman L, Steingart R, Germain M. Crescentic glomerulonephritis and eosinophilic interstitial infiltrates in a patient with hypereosinophilic syndrome. Postgrad Med J. 1995;71:175-178.
91. Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Briet report: clonal proliferation ot type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535-538.
92. Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8-T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med. 1996;183:1071-1082.
93. Brugnoni D, Airo P, Rossi G, et al. CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood. 1996;87:1416-1422.
94. Roulosse F, Schandene L, Sibille C, et al. T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood. 1999;94:994-1002.
95. Bank I, Amariglio N, Reshef A, et al. The hypereosinophilic syndrome associated with CD4+CD3-helper type 2 (Th2) lymphocytes. Leuk Lymphoma. 2001;42:123-133.
96. Brugnoni D, Airo P, Tosoni C, et al. CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia. 1997;11:1983-1985.
97. Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol. 2000;109:540-548.
98. Kawasaki A, Mizushima Y, Matsui S, Hoshino K, Yano S, Kitagawa M. A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report. Tumori. 1991;77:527-530.
99. Endo M, Usuki K, Kitazume K, Iwabe K, Okuyama Y, Urabe A. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol. 1995;71:313-314.
100. Catovksy D, Bernasconi C, Verdonck PJ, et al. The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients. Br J Haematol. 1980;45:523-534.
101. Takai K, Sanada M. Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol. 1991;54:231-239.
102. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol. 2003;122:173-179.
103. Weinteld A, Westin J, Swolin B. Ph1-negative eosinophilic leukemia with trisomy 8. Scand J Haematol. 1977;18:413-420.
104. Guitard AM, Horschowski N, Mozziconacci MJ, et al. Hypereosinophilic syndrome in childhood: trisomy 8 and transformation to mixed acute leukaemia. Nouv Rev Fr Hematol. 1994;35:555-559.
105. Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. Alpha-interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood. 1995;85:2284-2285.
106. Ma SK, Kwong YL, Shek TW, et al. The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol. 1999;30:864-868.
107. Myint H, Chacko J, Mould S, Ross F, Oscier DG. Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation. Br J Haematol. 1995;90:462-464.
108. Duell T, Mittermuller J, Schmetzer HM, Kolb HJ, Wilmanns W. Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32). Cancer Genet Cytogenet. 1997;94:91-94.
109. Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B, Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol. 2000;79:95-98.
110. Pardanani A, Reeder T, Ll CY, Tefferi A. Eosinophils are derived convert from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res. 2003;27:883-885.
111. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of inversion 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med. 1983;309:630-636.
112. Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JKH, Hayhoe FGJ 8;21 translocation in acute granulocytic leukemia: cytological, cytochemical, and clinical features. Br J Haematol. 1984;56:199-213.
113. Song HS, Park SK. A case of monosomy-7 eosinophilic leukemia and neurofibromatosis, terminated with disseminated cryptococcosis. Korean J Intern Med. 1987;2:131-134.
114. Harrington DS, Peterson C, Ness M, Sanger W, Smith DM, Vaughan W. Acute myelogenous leukemia with eosinophilic differentiation and trisomy-1. Am J Clin Pathol 1988;90:464-469.
115. Broustet A, Bernard P, Dachary D, et al. Acute eosinophilic leukemia with a translocation (10p+; 11q-). Cancer Genet Cytogenet. 1986;1:327-333.
116. Bhambhani K, Inoue S, Tyrkus M, Gohle N. Acute myelomonocytic leukemia type M4 with bone marrow eosinophilia and t(5;16)(q33;q22). Cancer Genet Cytogenet. 1986;20:187-188.
117. Mecucci C, Bosly A, Michaux JL, Broeckaert-Van Orshoven A, Van den Berghe H. Acute nonlymphoblastic leukemia with bone marrow eosinophilia and structural anomaly of chromosome 16. Cancer Genet Cytogenet. 1985;17:359-363.
118. Matsushima T, Murakami H, Kim K, et al. Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. Am J Hematol. 1995;50:110-115.
119. La Starza R, Trubia M, Testoni N, et al. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica. 2002;87:789-794.
120. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316.
121. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347:481-487.
122. Sato H, Danbara M, Tamura M. Morite M. Eosinophilic leukemia with a t(2;5)(p23;q35) translocation. Br J Haematol. 1994;87:404-406.
123. Darbyshire PJ, Shortland D, Swansbury GJ, Sadler J, Lawler SD, Chessells JM. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation. Br J Haematof. 1987;66:483-486.
124. Jani K, Kempski HM, Reeves BR, A case of myelodysplasia with eosinophilia having a translocation t(5;12)(q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol. 1994;87:57-60.
125. Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol. 2003;120:251-256.
126. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the 1(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102:4187-4190.
127. Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphoblastic leukemia with eosinophilia. Blood. 1990;76:285-289.
128. Popovici C, Zhang B, Gregoire MJ, et al. The t(6; 8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, 10 fibroblast growth factor receptor 1. Blood. 1999;93:1381-1389.
129. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with f(8;9)(p12;q33). Blood. 2000;95:1788-1796.
130. Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci U S A. 1998;95:5712-5717.
131. Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. 2001;98:3778-3783.
132. Guasch G, Popovici C, Mugneret F, et al. Endogenous retroviral sequence is fused to FGFRt kinase in the 8p12 sfem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood. 2003;101:286-288.
133. Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med. 1978;89:167-172.
134. Chusid MJ, Dale DC. Eosinophilic leukemia. Remission with vincristine and hydroxyurea. Am J Med. 1975;59:297-300.
135. Cofrancesco E. Cortellaro M, Pogliani E, Boschetti C, Salavatore M, Polli EE. Response to vincristine treatment in a case of idiopathic hypereosinaphilic syndrome with multiple clinical manifestations. Acta Haematol. 1984;72:21-25.
136. Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pedialr Hematol Oncol. 1992;14:348-351.
137. Lee JH, Lee JW, Jang CS, et al. Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome. Yonsei Med J. 2002;43:267-270.
138. Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826-2827.
139. Bourrat E, Lebbe C, Caivo F. Etoposide for treating the hypereosinophilic syndrome. Ann Intern Med. 1994;121:899-900.
140. Luciano L, Catalano L, Sarrantonio C, Guerriero A, Califano C, Rotoli B. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica. 1999;84:651-653.
141. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-α in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol. 1998;58:137-141.
142. Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol. 1996;92:176-183.
143. Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J Allergy Clin Immunol. 1994;94:1318-1326.
144. Ceretelli S, Capochiani E, Petrini M. Interferon-alphana in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol. 1998;77:161-164.
145. Yoon TY, Ann GB, Chang SH. Complete remission of hypereosinophilic syndrome atter interferon-alpha therapy: report of a case and literature review. J Dermatol. 2000;27:110-115.
146. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E), and granulocyte macrophage (CFU-GM) progenitor cells. J Immunol. 1983;131:1300-1305.
147. Schandene L, Dei Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest. 1996;97:309-315.
148. Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood. 1996;87:2354-2360.
149. Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol. 1991;62:230-231.
150. Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics, 1997;99:630-633.
151. Ueno NT, Zhao S, Robertson LE, Consuli U, Andreeff M. 2-chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia. 1997;11:1386-1390.
152. Vazquez L, Caballero D, Canizo CD, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelo fibrosis. Bone Marrow Transplant. 2000;25:217-218.
153. Chockalingam A, Jalil A, Shadduck RK, Lister J. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant. 1999;23:1093-1094.
154. Basara N, Markova J, Schmetzer B, et al. Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Leuk Lymphoma. 1998;32:189-193.
155. Sigmund DA, Fiessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:647-648.
156. Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol. 1996;51:164-165.
157. Sadoun A, Lacolle L, Delwail V, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant. 1997;19:741-743.
158. Juvonen E, Volin L, Kopenen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant. 2002;29:457-458.
159. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119:131-134.
160. Archimbaud E, Guyotat D, Guillaume C, Godard J, Fiere D. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol. 1988;27:302-303.
161. Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol. 1995;90:213-215.
162. Weyman AE, Rankin R, King H. Loeffler's endocarditis presenting as mitral and trucuspid stenosis. Am J Cardiol. 1977;40:438-444.
163. Chandra M, Pettigrew RI, Eley JW, Oshinski JN, Guyton RA. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. Ann Thorac Sung. 1996;62:1856-1858.
164. Blacklock HA, Cleland, JF, Tan P, Pillai VM. The hypereosinophilic syndrome and leukapheresis. Ann Intern Med. 1979;91:650-651.
165. Davies J, Spry C. Plasma exchange or leukapheresis in the hypereosinophilic syndrome. Ann Intem Med. 1982;96:791.
166. Chambers LA, Leonard SS, Whatmough AE, Weller PF, Bubley GJ, Kruskall MS. Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis. Prog Clin Biol Res. 1990;337:83-85.
167. Ault P, Cortes J, Koller C, Kaled ES, Kanfarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
168. Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med. 1998;91:492-493.
169. Schaffer JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylafe. MedGenMed. 2001;3:9.
170. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
171. Pardanani A, Reeder T, Porrata L, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
172. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714-4716.
173. Preker PJ, Lingner J, Minvielle-Sebastia L, Keller W. The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poy(A) polymerase. Cell. 1995;81:379-389.
174. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
175. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103:473-478.
176. Pardanani A, Ketteriing RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood, 2003;102:3093-3096.
177. Griffin JH, Loung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A. 2003;100:7830-7835.
178. Helmling S, Zhelkovsky A, Moore CL, Fip1 regulates the activity of Poly(A) polymerase through multiple interactions. Mot Cell Biol. 2001;21:2026-2037.
179. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease. Cancer Cell. 2003;3:459-469.
180. Valgeirsdottir S, Paukku K, Silvennoinen O, Heldin CH, Claesson-Welsh L. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene. 1998;16:505-515.
181. Yu J, Deuel TF, Kim HR. Platelet-derived growth tactor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes FDGF receptor-beta-induced phenotypic transformation. J Biol Chem. 2000;275:19076-19082.
182. Yang J, Symes K, Mercola M, Schreiber SL. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol. 1998;8:11-18.
183. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13:7587-7595.
184. Carroll M, Tornasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth tactor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that selt-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850.
185. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine
186. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5; 10)(q33;q22). Blood. 2001;97:3910-3918.
187. Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem. 1999;274:22328-22336.
188. Lacronique V, Boureaux A, Vatte VD, et al. A TELJAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312.
189. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
190. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations in c-kit in human gastrointestinal tumors. Science. 1998;279:577-580.
191. Irusta PM, Luo Y, Bakhl O, Lai CC, Smith SO, DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the plalelet-derived growth factor beta receptor. J Biol Chem. 2002;277:38627-38634.
192. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal shornal tumors. Science. 2003;299:708-710.